ICL Stock Analysis: ICL Israel Chemicals | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 7.060m USD | 12M Return: -0.1% | IL0002810146 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.12M
EPS Trend: -78.0%
Qual. Beats: 1
Rev. Trend: -10.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICL Group Ltd is an Israel-based specialty minerals and chemicals company headquartered in Tel Aviv-Yafo, operating through four business segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions. The company was incorporated in 1968 and was renamed from Israel Chemicals Ltd to ICL Group Ltd in May 2020.
The Industrial Products segment produces bromine as a by-product of the potash production process, along with bromine-based compounds, phosphorus-based flame retardants, and various grades of potash, salt, magnesium chloride, and magnesia products. The Potash segment produces and sells potash, salt, magnesium, magnesium alloys, electricity, chlorine, and sylvinite. The Phosphate Solutions segment manufactures specialty phosphate products, including phosphate-based fertilizers, sulphuric and green phosphoric acid, phosphate salts and acids, functional food ingredients, and phosphate additives. The Growing Solutions segment offers nitrogen, potash, and phosphate-based fertilizers, including water-soluble specialty and controlled-release products, secondary nutrients, bio-stimulants, soil conditioners, seed treatments, and adjuvants, as well as digital platforms for farmers and agronomists.
ICL sells its products across a wide range of end markets, including pharmaceutical, food, oil and gas, de-icing, building and construction, oral care, paints and coatings, energy storage, water treatment, electronics, automotive, agriculture, textiles, tire manufacturing, and healthcare industries, as well as to power plants and battery producers. Distribution is handled through marketing companies, agents, and distributors. The company is listed on the NYSE under the ticker ICL and is classified within the Materials sector, specifically the Fertilizers & Agricultural Chemicals sub-industry.
- Potash price swings drive bulk fertilizer segment margins
- Bromine demand rises with EV battery and flame retardant markets
- Specialty phosphate margins expand on food and healthcare pricing
| Net Income: 305.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -1.33 > 1.0 |
| NWC/Revenue: 21.52% < 20% (prev 26.02%; Δ -4.49% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.08b > Net Income 305.0m |
| Net Debt (2.89b) to EBITDA (1.46b): 1.98 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -0.11% < -2% |
| Gross Margin: 30.63% > 18% (prev 32.29%; Δ -1.66% > 0.5%) |
| Asset Turnover: 60.34% > 50% (prev 56.19%; Δ 4.15% > 0%) |
| Interest Coverage Ratio: 2.47 > 6 (EBIT TTM 818.0m / Interest Expense TTM 331.0m) |
| A: 0.13 (Total Current Assets 4.50b - Total Current Liabilities 2.84b) / Total Assets 13.2b |
| B: 0.45 (Retained Earnings 5.90b / Total Assets 13.2b) |
| C: 0.06 (EBIT TTM 818.0m / Avg Total Assets 12.8b) |
| D: 0.91 (Book Value of Equity 6.15b / Total Liabilities 6.75b) |
| Altman-Z'' = 3.67 = AA |
| DSRI: 1.03 (Receivables 1.64b/1.43b, Revenue 7.71b/6.95b) |
| GMI: 1.05 (GM 32.29% / 30.63%) |
| AQI: 1.02 (AQ_t 0.12 / AQ_t-1 0.12) |
| SGI: 1.11 (Revenue 7.71b / 6.95b) |
| TATA: -0.06 (NI 305.0m - CFO 1.08b) / TA 13.2b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of September 05, 2026, the stock is trading at USD 5.87 with a total of 883,244 shares traded. Over the past week, the price has changed by +5.89%, over one month by +15.14%, over three months by +0.67% and over the past year by -0.10%.
Current recommended Stop Loss: 5.60 (which is 4.6% or 2.1 ATR below the current price).
ICL Israel Chemicals has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold ICL.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.8 | -1% |
P/E Trailing = 23.3333
P/E Forward = 55.5556
P/S = 0.9492
P/B = 1.1908
P/EG = 9.44
Revenue TTM = 7.71b USD
EBIT TTM = 818.0m USD
EBITDA TTM = 1.46b USD
Long Term Debt = 2.65b USD (from longTermDebt, last quarter)
Short Term Debt = 646.0m USD (from shortTermDebt, last quarter)
Debt = 3.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 255.0m
Net Debt = 2.89b USD (calculated: Debt 3.55b - CCE 662.0m)
Enterprise Value = 9.95b USD (7.06b + Debt 3.55b - CCE 662.0m)
Interest Coverage Ratio = 2.47 (Ebit TTM 818.0m / Interest Expense TTM 331.0m)
EV/FCF = 34.20x (Enterprise Value 9.95b / FCF TTM 291.0m)
FCF Yield = 2.92% (FCF TTM 291.0m / Enterprise Value 9.95b)
FCF Margin = 3.77% (FCF TTM 291.0m / Revenue TTM 7.71b)
Net Margin = 3.95% (Net Income TTM 305.0m / Revenue TTM 7.71b)
Gross Margin = 30.63% ((Revenue TTM 7.71b - Cost of Revenue TTM 5.35b) / Revenue TTM)
Gross Margin QoQ = 31.10% (prev 30.94%)
Tobins Q-Ratio = 0.75 (Enterprise Value 9.95b / Total Assets 13.2b)
Interest Expense / Debt = 9.32% (Interest Expense 331.0m / Debt 3.55b)
Taxrate = 33.95% (184.0m / 542.0m)
NOPAT = 540.3m (EBIT 818.0m * (1 - 33.95%))
Current Ratio = 1.58 (Total Current Assets 4.50b / Total Current Liabilities 2.84b)
Debt / Equity = 0.58 (Debt 3.55b / totalStockholderEquity, last quarter 6.15b)
Debt / EBITDA = 1.98 (Net Debt 2.89b / EBITDA 1.46b)
Debt / FCF = 9.93 (Net Debt 2.89b / FCF TTM 291.0m)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.39% (Net Income 305.0m / Total Assets 13.2b)
RoE = 5.02% (Net Income TTM 305.0m / Total Stockholder Equity 6.08b)
RoCE = 9.37% (EBIT 818.0m / Capital Employed (Equity 6.08b + L.T.Debt 2.65b))
RoIC = 5.09% (NOPAT 540.3m / Invested Capital 10.6b)
WACC = 7.27% (E(7.06b)/V(10.6b) * Re(7.83%) + D(3.55b)/V(10.6b) * Rd(9.32%) * (1-Tc(0.34)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 48.03 | Cagr: 0.01%
[DCF] Terminal Value 73.10% ; FCFF base≈349.7m ; Y1≈306.7m ; Y5≈247.8m
[DCF] Fair Price = 0.84 (EV 3.98b - Net Debt 2.89b = Equity 1.09b / Shares 1.29b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -78.05 | EPS CAGR: -26.44% | SUE: 0.84 | # QB: 1
Revenue Correlation: -10.60 | Revenue CAGR: -0.56% | SUE: 2.10 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.11 | Chg30d=+0.47% | Revisions=-40% | Analysts=4
EPS current Year (2026-12-31): EPS=0.42 | Chg30d=+0.24% | Revisions=-25% | GrowthEPS=+16.6% | GrowthRev=+14.9%
EPS next Year (2027-12-31): EPS=0.44 | Chg30d=-2.16% | Revisions=-40% | GrowthEPS=+4.9% | GrowthRev=-0.6%
[Analyst] Revisions Ratio: -62% (up=0, down=5)